S_inmary A novel "'In ligand (a C-functionalised derivative of 1,4,7-triazacyclononanetriacetic acid), termed 9N3, was covalently attached to chimeric B72.3, labelled with "'In and compared with ".In-labelled chimeric B72.3 diethylenetriaminepentaacetic acid (DTPA) cyclic anhydnde conjugate (cDTPA) and a C-linked derivative of DTPA (CT-DTPA) in athymic mice bearing human colon carcinoma xenografts. Significant differences in biodistribution were observed between 9N3 and cDTPA conjugates especially in the tumour uptake and blood, liver, femur and colon levels at 24, 48 and 144 h. Significantly higher tumour uptake was observed for "'In-cB72.3-9N3 compared with "'.In-cB72.3-cDTPA at all time points. Radiolocalisation (RI) indices increased with time for the 9N3 conjugate but remained constant for the cDTPA conjugate. The biodistribution of "'In-labelled cB72.3-CT-DTPA was similar to that of ".In-labelled cB72.3-9N3 except for elevated kidney levels. A 12N4 macrocycle (a C-functionalised derivative of 1,4,7,10-tetraazacyclododecanetetraacetic acid) was also tested for its ability to chelate "'In and its biodistribution examined. Labelled conjugates with this macrocycle were more difficult to prepare in a stable form but gave a very similar biodistribution to the 9N3 macrocycle conjugate. Macrocycle-antibody conjugates of this type offer considerable promise for tumour imaging in patients.
Many studies over recent years have shown that radiolabelled antibodies to tumour-associated antigens can be successfully used for imaging a variety of tumour types (Davidson et al., 1991; Lamki et al., 1991; Goldenberg et al., 1993) . Several gamma-emitting radioisotopes have been used for tumour imaging, with one of the most widely used being indium-l 1 ("'In). "'In-labelled antibodies enjoy a number of advantages over those labelled with other isotopes, including a favourable gamma energy for imaging (173 and 274 keV), a 2.8 day half-life and the absence of specific mechanisms to remove the isotope from the antibody, as is the case with the deiodination of iodine-labelled antibodies.
Attachment of "'In to monoclonal antibodies requires the use of a chelator, the most widely used for indium being DTPA. DTPA is normally attached to antibody as the cyclic anhydride, which results in the attachment through one of the chelation arms (Hnatowich et al., 1983) . The chelation of "'In by conjugates of this type is relatively weak, and the use of these in vivo has led to significant instability of the labelled conjugate in both animal model studies and patients (Hnatowich et al., 1985) . This instability is particularly manifested by the accumulation of high levels of "'In in the liver (Shumacher et al., 1990) , possibly as a result of release of free "'In, which is then bound by serum transferrin and transported to the liver (Meares et al., 1984) . Recently, novel bifunctional derivatives of DTPA have been devised in which the carbon backbone of the chelate has a linking group inserted for attachment to the antibody such that all eight coordination sites on DTPA are preserved (Brechbiel et al., 1986) . These conjugates are more stable than those produced with cDTPA, give rise to lower liver uptake in animals and indeed have allowed imaging of liver metastases in patients (Divgi et al., 1991) .
There has also been considerable interest in the development of macrocycic chelators for the attachment of radioisotopes to antibodies (Moi et al., 1988; Cox et al., 1989; Craig et al., 1989; Deshpande et al., 1990) . It has been shown that the macrocycle 1,4,7-triazacyclononanetriacetic acid (termed 9N3) can form very stable complexes with "'In (log KI 26.2/H20, 298KI = 0.1) and the X-ray structure of the indium complex has been solved (Broan et al., 1991) . Bifunctional derivatives of this macrocycle incorporating a maleimide spacer arm have been synthesised for attachment to an antibody without loss of any of the macrocycic chelation capacity (Craig et al., 1989) . This study was therefore undertaken to determine the comparative in vivo behaviour of "'In-9N3 conjugates with the relevant clinical control DTPA and a bifunctional DTPA derivative using an antibody to a tumour-associated antigen. The bifunctional DTPA derivative used in this study was CT-DTPA (Harrison et al., 1991) .
In addition, we have developed a series of macrocycic chelators for the attachment of the beta-emitting isotope yttrium-90 to antibodies (Cox et al., 1989) . One of these (termed 12N4), has been shown to form stable complexes with 9'Y that have superior biodistribution properties to DTPA and bifunctional DTPA derivatives Harrison et al., 1991) . This macrocycle is also capable of forming a complex with "'In, and thus is also a candidate for clinical use in imaging studies. This would allow the use of the "'In-12N4 conjugate as a tracer for corresponding 9Y-12N4 conjugates, allowing accurate measurements of radiation dosimetry from the same antibody preparation. Therefore the biodistribution of "'In-12N4 conjugates has also been compared with that of the 9N3 macrocycle.
The antibody selected for these studies was a recombinant chimeric version of B72.3 (Whittle et al., 1987; Colcher et al., 1989) . B72.3 is a murne antibody which reacts with a tumour-associated glycoprotein (TAG 72) found on a large number of human neoplasms including colon, breast and ovarian carcinomas. This antibody has been evaluated in iodinated form in animals King et al., 1992) and in patients (Begent et al., 1990; Khazaeli et al., 1991) .
Materis and methods
Preparation and characterisation of chimeric B72.3 immuioconjugates 0.1 M sodium hydrogen carbonate pH 8.0 containing 2 mM EDTA, and was incubated with 2-iminothiolane hydrochloride (Sigma 1-6256; 1 mM) at 20C for 30 min. Unreacted reagent was removed by desalting the mixture on a prepacked Sephadex G-25 gel filtration column (PD-10, Pharmacia) equilibrated in the same buffer. An aliquot was removed for titration with 4,4'-dithiodipyridine (Sigma D-8136; DTDP) to determine the number of thiols generated (Lyons et al., 1990) . This treatment typically introduced 1 thiol per chimeric B72.3. A malimide derivative of the chelator [9N3 macrocycle (CT82, Figure 1 ), CT-DTPA (CT74, Figure 1 ) or 12N4 macrocycle (C-177, Figure 1) (Meares et al., 1984) . The remaining mixture was desalted into 0.1 M sodium acetate buffer pH 5.0. The buffers used in the preparation of the immunoconjugates contained 2 mM EDTA (except the radiolabelling buffer) and were made from the highest grade reagents available and made up using water from the Millipore Milli Q SP reagent water system to prevent metal contamination of the chelates.
The immunoconjugates were characterised and checked for purity by high-performance liquid chromatography (HPLC) gel filtration (DuPont Zorbax bioseries GF-250 column) eluted with 0.2 M phosphate buffer pH 7.0 and by sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE) under both reducing and non-reducing conditions. The immunoreactivity of the conjugates was determined by enzyme-linked immunosorbent assay (ELISA) as previously described (King et al., 1992) .
"'In labelling of cB723 conjugates Indium-l11 chloride (Amersham; 2 mCi, volume 200 LI) in 40mM hydrochloric acid was added to the immunoconjugates (at 5 mg ml-') in 0.1 M sodium acetate pH 5.0 to give a potential specific activity of 1.2;LCin-g1. The mixtures were left at 20C for lS min and then quenched by the addition of free DTPA to 5 mM. The extent of indium binding and integrity of the conjugates was determined by injecting an aliquot onto an HPLC gel filtration column connected in series to a UV detector and radiochemical detector. The HPLC mobile phase was 0.2 M sodium phosphate pH 7.0 containing 5 mM DTPA eluted at a flow rate of 1.0 ml min-'. The radiolabelled cB72.3 conjugates were purified by HPLC gel filtration under the same conditions, followed by buffer exchange into phosphate-buffered saline (PBS). In the case of the 12N4 macrocycle the HPLCpurified material was maintained overnight at 20C in the presence of 5 mM DTPA to remove loosely bound "1'In, followed by buffer exchange into phosphate-buffered saline (PBS).
The radiochemical purity of each radiolabelled conjugate was determined by reinjecting an aliquot of each preparation onto a DTPA-stripped HPLC gel filtration column run under the same conditions. This was corroborated by an instant thin-layer chromatography (ITLC) assay (Meares et al., 1984) , in which aliquots of the radiolabelled immunoconjugates were spotted in duplicate onto preactivated (heated to 1 I0C for 30 min) mILC plates (Gelman Sciene), and developed with 0.1 M sodium citrate buffer pH 5.0. The strips were cut into four pieces and counted using an LKB gamma counter. In this assay free "'In was complexed, migrating with the solvent front, whereas antibody-bound "'In remained at the origin. The radiochemical purity was calculated as the percentage of counts rmaining at the origin divided by the total counts (from the four pieces) multiplied by 100.
Animal tumour model studies The human colorectal carcinoma line LS-74T expresses high levels of TAG-72 (the antigen for B72.3) when grown as a solid tumour, and the animal xenograft model has been described in detail elsewhere (Colcher et al., 1986; Lundy et al., 1986; Brown et al., 1987; Esteban et al., 1987 (Paik et al., 1985; Sakahara et al., 1985) . For the macrocycle and the CT-DTPA conjugates, this was achieved by reacting a small aliquot of the antibody with 4,4'-dithiodipyridine (DTDP) immediately after 2-iminothiolane modification to determine the number of generated thiol groups and then again on another aliquot after reaction with the appropriate maleimide linker to determine how many thiol groups were remaining. The water-20% 1 M ammonium acetate, pH 6.5-10% acetronitrile. The labelled linkers were then incubated in 5 mM DTPA for up to 24 h at room temperature, and the loss of the "'IIn from the macrocycle was monitored by the increase in the "'In-DTPA peak on HPLC. There was a loss of <3% of "'In from the 9N3 linker, whereas there was >40% loss from the 12N4 linker over the same time period.
A similar phenomenon to that seen with the free macrocycle derivatives was observed with the "'In-labelled 9N3 and 12N4 immunoconjugates when the HPLC-purified samples (in 0.2 M sodium phosphate-5 mM DTPA, pH 7.0) were assessed for radiochemical purity. One IgG-associated peak for the 9N3 conjugate was seen, whereas two peaks were seen for the 12N4 conjugate found to be IgG and low molecular weight material ("'In-DTPA), the latter accounting for 25%
of the total counts. Figure 2 shows Table II ). ( ), 9N3 (from Table III (Table II) that the tumour uptake was significantly higher for the 9N3 conjugate at each time point (P<0.05) compared with the cDTPA conjugate, but similar to the CT-DTPA conjugate. This was a result of the significantly lower blood levels (P<0.05) for the cDTPA conjugate. The liver levels were low for all three conjugates but differed significantly for cDTPA at 144 h (P<0.01). Another significant difference in biodistribution was seen in the femur, where the levels were higher for the cDTPA conjugate (P<0.05). Levels of activity in the kidney were relatively high and variable with this chimeric antibody for all chelates, and especially for CI-DTPA. This is known to be a particular property in four known cases (three unpublished) of human IgG4 antibodies resulting from the proportion of human IgG4 which does not fully form its hinge disulphide bonds (Angal et al., 1993, and unpublished data) . Overall the most favourable distribution was observed for the 9N3 conjugate. A further biodistribution study was then undertaken to compare the tissue distribution of "'In-labelled 9N3 macrocycle conjugate with a 12N4 macrocycle conjugate labelled with "'In and stripped with DTPA as described. The results at 24, % and 144 h are shown in Table III . In this experiment the difference between the two conjugates was not so pronounced. However, the differences were mainly seen at 144 h, when the liver and the femur levels were significantly higher for the 12N4 conjugate (P <0.05).
To allow comparison of tissues without the contribution of differences in blood-associated activity, the tissue-to-blood ratios were calculated (% ID g-' tissue divided by % ID g-' blood). The ratios were obtained by calculating the means (and standard error) of the ratios of individual mice in each group. These ratios emphasised the difference between the chelates, especially with respect to the spleen, liver, colon and femur (Figure 3) , instability of the cDTPA conjugate being seen especially at the longer time points. Some variation was observed in the blood levels between the different cB72. Table II ), ( ) 9N3 (from Table III macrocycle labelling to particularly high efficiency. The 12N4 macrocycle is somewhat more difficult to use with "'In because of the need for a DTPA stripping step to remove loosely bound "'In.
Great care was taken in the preparation of labelled conjugates for in vivo studies. They were prepared by protocols designed to minimise antibody damage and purified by HPLC to produce high-quality labelled conjugates. This has been reported to improve biodistribution and consequently scintigraphic images (Esteban et al., 1987) . Indeed, as a result our own biodistribution data with the cDTPA conjugate were seemingly better than published data obtained with the murine version of the B72.3 antibody (Brown et al., 1987; Esteban et al., 1987) .
The "'In-cB72.3-9N3 conjugate was shown to be more stable in vivo than cDTPA, as evidenced by significantly lower liver, femur and colon uptake. This was particularly emphasised by the tissue-to-blood ratios, which increased with time for the cDTPA conjugate as "'In was lost from the blood and accumulated in a range of tissues. The bifunctional DTPA derivative, CT-DTPA, also showed an improved biodistribution over cDTPA, as expected by comparison with other substituted DTPA chelates . Comparison of CT-DTPA and the 9N3 macrocycle biodistributions showed them to be very similar, with the major difference being the lower kidney levels for 9N3. Both CT-DTPA and the 9N3 macrocycle are attractive as chelators for "'In, with 9N3 being preferable.
The biodistribution of the 12N4 macrocycle conjugate showed poorer tumour-to-tissue ratios than the 9N3 macrocycle conjugate, however the data showed that both of these macrocycles are capable of "'In chelation in a stable form. The attraction of using the 12N4 macrocycle for "'In is that this macrocycle can also chelate 9'Y in a very stable form with improved biodistribution over cDTPA and CT-DTPA Harrison et al., 1991) . This would allow the use of the same antibody conjugate for both imaging with "'In and therapy with 9'Y. However, the more difficult and time-consuming labelling procedure to achieve stable "'In uptake by 12N4 makes this alternative less attractive. The importance of this procedure is emphasised by the work of Snook et al. (1991) , who found that high liver levels of activity were seen (similar to those seen with cDTPA) when a similar derivative of 12N4 was tested without a DTPA stripping step in the labelling procedure.
Some preliminary clinical studies have been reported using a similar 12N4 macrocycle to that used in this study, attached to the antibodies HMFG1 and a humanised version of H17E2 (Hird et al., 1991; Kosmas et al., 1992) . In these studies an immune response was generated by the patients to the macrocycle, which appeared to act as a hapten when attached to the antibody. The macrocyclic ligand used was lined to the antibody through a benzyl-containing structure, and is therefore a very different type of structure to those used here, in which no aromatic rings are present. In addition, high levels of aggregate (up to 16%) were present in the preparations used by Kosmas et al. (1992) . However, the immunogenicity of the 9N3 and 12N4 macrocycic conjugates used in this report remains to be evaluated.
Overall, the malemide derivative of the 9N3 macrocycle is an ideal reagent for the attachment of "'In to antibodies in a stable form, it can be attached in a simple procedure without causing antibody damage, can be labelled to high efficiency and gives rise to a very stable conjugate in biodistribution studies. Indeed, a preliminary report of clinical data with this reagent attached to the antibody SM3 has revealed superior tumour imaging to that obtained with the same antibody labelled with DTPA (Granowska et al., 1991) . The combination of stable attachment methods for radioisotopes such as the macrocyclic ligands reported here with recombinant humanised antibodies, which may allow repeat dosing through reduction of the immune response (Adair, 1992) , should allow the development of a new generation of radiolabelled antibody conjugates for tumour imaging and therapy.
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